myLaminin Perspectives

earn how sponsors can manage protocol deviations, amendments, eTMF documentation, and regulatory compliance in multi-site clinical trials under evolving ICH E6(R3) expectations.

Clinical trial start-up delays continue to impact site activation, budgets, and timelines due to fragmented workflows across feasibility, contracting, IRB/REB approvals, training, and system readiness. This article explains how CTMS platforms, integrated research systems, and AI-driven automation reduce inefficiencies by centralizing processes, improving visibility, and accelerating trial activation across global clinical research environments.

ICH E6 (R3) is reshaping clinical trial compliance across Canada, the U.S., EU, UK, and Australia. The updated Good Clinical Practice (GCP) guideline emphasizes Quality by Design, proactive risk management, audit trail traceability, sponsor oversight, informed consent, data integrity, and inspection readiness. myLaminin helps research teams and sponsors manage multi-site clinical trials with real-time oversight, CTQ monitoring, compliant eConsent, secure audit trails, and val

myLaminin, the most complete, integrated, and secure Research Data Management (RDM) platform on the market.

No matter what field you are working in, good data collection and management isn’t just nice to have, it's essential.